Chemo-immunotherapy Plus Thoracic Radiotherapy in Extensive Stage Small-cell Lung Cancer
Status:
Recruiting
Trial end date:
2029-10-01
Target enrollment:
Participant gender:
Summary
Studies have shown that combining chemotherapy and immune checkpoint inhibitors (ICI)
prolongs survival compared with chemotherapy alone in extensive stage small-cell lung cancer
(ES SCLC), but the survival benefit is modest. The main aim of this trial is to investigate
whether there is a synergistic/additive effect of concurrent thoracic radiotherapy in ES SCLC
patients receiving carboplatin/etoposide/durvalumab.
Phase:
Phase 3
Details
Lead Sponsor:
Norwegian University of Science and Technology
Collaborators:
Alesund Hospital Drammen sykehus Erasmus Medical Center Gävle Hospital Haukeland University Hospital Helse Fonna Helse Nord-Trøndelag HF Helse Stavanger HF Karolinska University Hospital National Cancer Institute, Lithuania North Estonia Medical Centre Odense University Hospital Oslo University Hospital Rigshospitalet, Denmark Sahlgrenska University Hospital, Sweden St. Olavs Hospital Sykehuset Innlandet HF University Hospital of North Norway University Hospital, Akershus